In vitro and in vivo characterization of a combination chemotherapy formulation consisting of vinorelbine and phosphatidylserine

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 65, Issue 3, 2007, Pages 289-299

  Webb, Murray S ^a   Johnstone, Sharon ^a   Morris, Tara J ^a   Kennedy, Allison ^a   Gallagher, Ryan ^a   Harasym, Natashia ^a   Harasym, Troy ^a   Shew, Clifford R ^a   Tardi, Paul ^a   Dragowska, Wieslawa H ^b   Mayer, Lawrence D ^a,b,c   Bally, Marcel B ^b,c,d  

^a Celator Pharmaceuticals Corp   (Canada)

^b Department of Advanced Therapeutics ^*  (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Combination therapy; Drug delivery; Phosphatidylserine; Synergy; Vinorelbine

Indexed keywords

DILAUROYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDYLCHOLINE; LIPID; LIPOSOME; NAVELBINE; PHOSPHATIDYLSERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENTIATION; ENCAPSULATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; DRUG DESIGN; DRUG SYNERGISM; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LIPOSOMES; LUNG NEOPLASMS; MICE; PHOSPHATIDYLSERINES; TECHNOLOGY, PHARMACEUTICAL; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33847311776     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2006.10.007     Document Type: Article

References (42)

1. Bertram J.S. The molecular biology of cancer. Mol. Aspects Med. 21 (2001) 167-223
2. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin. Oncol. 24 4 Suppl. 10 (1997) S10-3-S10-10
3. Frei III E., Elias A., Wheeler C., Richardson P., and Hryniuk W. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin. Cancer Res. 4 (1998) 2027-2037
4. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 270-355
5. Park J.W. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 4 (2002) 95-99
6. Rosenthal E., Poizot-Martin I., Saint-Marc T., Spano J.P., and Cacoub P. DNX study group, phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. Am. J. Clin. Oncol. 25 (2002) 57-59
7. Pestalozzi B., Schwendener R., and Sauter C. Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Ann. Oncol. 3 (1992) 445-449
8. Boehlke L., and Winter J.N. Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drug. Expert Opin. Biol. Ther. 6 (2006) 409-415
9. Kehrer D.F., Bos A.M., Verweij J., Groen H.J., Loos W.J., Sparreboom A., de Jonge M.J., Hamilton M., Cameron T., and de Vries E.G. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. J. Clin. Oncol. 20 (2002) 1222-1231
10. Abraham S.A., McKenzie C., Masin D., Ng R., Harasym T.O., Mayer L.D., and Bally M.B. In vitro and in vivo characterization of doxorubicin and vincristine co-encapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin. Cancer Res. 10 (2004) 728-738
11. Fadok V.A., and Henson P.M. Apoptosis: giving phosphatidylserine recognition an assist - with a twist. Curr. Biol. 13 (2003) R655-R673
12. Huigsloot M., Tijdens I.B., Mulder G.J., and van de Water B. Differential regulation of phosphatidylserine externalization and DNA fragmentation by caspases in anticancer drug-induced apoptosis of rat mammary adenocarcinoma MTLn3 cells. Biochem. Pharmacol. 62 (2001) 1087-1097
13. Uthaisang W., Nutt L.K., Orrenius S., and Fadeel B. Phosphatidylserine exposure in Fas type I cells in mitochondria-dependent. FEBS Lett. 545 (2003) 110-114
14. Ferraro-Peyret C., Quemeneur L., Flacher M., Revillard J.P., and Genestier L. Caspase-independent phosphatidylserine exposure during apoptosis of primary T lymphocytes. J. Immunol. 169 (2002) 4805-4810
15. Uchida K., Emoto K., Daleke D.L., Inoue K., and Umeda M. Induction of apoptosis by phosphatidylserine. J. Biochem. (Tokyo) 123 (1998) 1073-1078
16. Miyato Y., Ibuki Y., Ohyama H., Yamada T., and Goto R. Phosphatidylserine induces apoptosis in CHO cells without mitochondrial dysfunction in a manner dependent on caspases other than caspases-1, -3, -8 and -9. FEBS Lett. 504 (2001) 73-77
17. Iguchi K., Hirano K., Hamatake M., and Ishida R. Phosphatidylserine induces apoptosis in adherent cells. Apoptosis 6 (2001) 263-268
18. Campbell P.I. Toxicity of some charged lipids used in liposome preparations. Cytobios 37 (1983) 21-26
19. Mayhew E., Ito M., and Lazo R. Toxicity of non-drug-containing liposomes for cultured human cells. Exp. Cell Res. 171 (1987) 195-202
20. Kumagai K., Nabeshima S., Kato S., Watanabe M., and Ikuta K. Selective killing of HIV-infected cells by liposomes composed of dimyristoylphosphatidylcholine/phosphatidylserine/cholesterol. Antivir. Chem. Chemother. 2 (1991) 143-148
21. Fadok V.A., Bratton D.L., Rose D.M., Pearson A., Ezekewitz R.A.B., and Henson P.M. A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405 (2000) 85-90
22. Fadok V.A., de Cathelineau A., Daleke D.L., Henson P.M., and Bratton D.L. Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J. Biol. Chem. 276 (2001) 1071-1077
23. Wang L.G., Liu X.M., Kreis W., and Budman D.R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother. Pharmacol. 44 (1999) 355-361
24. Masuda A., Maeno K., Nakagawa T., Saito H., and Takahashi T. Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human cancers. Am. J. Pathol. 163 (2003) 1109-1116
25. O'Connor D.S., Wall N.R., Porter A.C., and Altieri D.C.A. p34 (cdc2) survival checkpoint in cancer. Cancer Cell 2 (2002) 43-54
26. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
27. Chou T.-C. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J. Theor. Biol. 39 (1976) 253-276
28. Bally M.B., Mayer L.D., Hope M.J., and Nayer R. Pharmacodynamics of liposomal drug carriers: methodological considerations. In: Gregoridis G. (Ed). Liposome Technology (1993), CRC Press 27-41
29. Hope M.J., Bally M.B., Webb G., and Cullis P.R. Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta 812 (1985) 55-65
30. Mayer L.D., Nayer R., Thies R.L., Boman N.L., Cullis P.R., and Bally M.B. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother. Pharmacol. 33 (1993) 17-24
31. Embree L., Gelmon K.A., Tolcher A.W., Hudon N.J., Heggie J.R., Dedhar C., Webb M.S., Bally M.B., and Mayer L.D. Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. J. Pharm. Biomed. Anal. 16 (1997) 675-687
32. Fidler I.J., Raz A., Fogler W.E., and Poste G. Pulmonary localization of intravenously injected liposomes. Recent Results Cancer Res. 75 (1980) 246-251
33. Chiu G.N.C., Bally M.B., and Mayer L.D. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim. Biophys. Acta 1510 (2001) 56-69
34. Webb M.S., Harasym T.O., Masin D., Bally M.B., and Mayer L.D. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer 72 (1995) 896-904
35. Haran G., Cohen R., Ba L.K., and Barenholz Y. Transmembrane ammonium sulphate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta 1151 (1993) 201-215
36. Fenske D.B., Wong K.F., Maurer E., Maurer N., Leenhouts J.M., Boman N., Amankwa L., and Cullis P.R. Ionophore-mediated uptake of ciprofloxacin and vincristine into large unilamellar vesicles exhibiting transmembrane ion gradients. Biochim. Biophys. Acta 1414 (1998) 188-204
37. Otsuka M., Goto K., Tsuchiya A., and Aramaki Y. Phosphatidylserine-specific receptor contributes to TGF-β production in macrophages through a MAP kinase, ERK. Biol. Pharm. Bull. 28 (2005) 1707-1710
38. Adlakha-Hutcheon G., Bally M.B., Shew C.R., and Madden T.M. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat. Biotech. 17 (1999) 775-779
39. Hoffman P.R., deCathelineau A.M., Ogden C.A., Leverrier Y., Bratton D.L., Daleke D.L., Ridley A.J., Fadok V.A., and Henson P.M. Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J. Cell Biol. 155 (2001) 649-659
40. Goren G., Gabizon A., and Barenholz Y. The influence of physical characteristic of liposomes containing doxorubicin on their pharmacological behaviour. Biochem. Biophys. Acta 1029 (1990) 285-294
41. Nii A., Utsugi T., Fan D., Denkins Y., Pak C., Brown D., van Hoogevest P., and Fidler I.J. Optimization of the liposomes encapsulating a new lipopeptides CGP 31362 for efficient activation of tumoricidal properties in monocytes and macrophages. J. Immunother. 10 (1991) 236-246
42. Schroit A.J., and Fidler I.J. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res. 42 (1982) 161-167